vs
豪洛捷（HOLX）与Trade Desk (The)（TTD）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Trade Desk (The)的1.2倍（$1.0B vs $846.8M），Trade Desk (The)净利率更高（22.1% vs 17.1%，领先5.0%），Trade Desk (The)同比增速更快（14.3% vs 2.5%），Trade Desk (The)自由现金流更多（$285.3M vs $215.2M），过去两年Trade Desk (The)的营收复合增速更高（31.3% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
The Trade Desk是来自美国的跨国科技企业，专注于实时程序化营销自动化领域的技术、产品与服务研发，可实现面向用户的个性化数字内容分发，为全球广告营销行业客户提供专业解决方案。
HOLX vs TTD — 直观对比
营收规模更大
HOLX
是对方的1.2倍
$846.8M
营收增速更快
TTD
高出11.7%
2.5%
净利率更高
TTD
高出5.0%
17.1%
自由现金流更多
TTD
多$70.1M
$215.2M
两年增速更快
TTD
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $846.8M |
| 净利润 | $179.1M | $186.9M |
| 毛利率 | 56.0% | 80.7% |
| 营业利润率 | 22.6% | 30.3% |
| 净利率 | 17.1% | 22.1% |
| 营收同比 | 2.5% | 14.3% |
| 净利润同比 | -10.9% | 2.6% |
| 每股收益（稀释后） | $0.79 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXTTD
| Q4 25 | $1.0B | $846.8M | ||
| Q3 25 | $1.0B | $739.4M | ||
| Q2 25 | $1.0B | $694.0M | ||
| Q1 25 | $1.0B | $616.0M | ||
| Q4 24 | $1.0B | $741.0M | ||
| Q3 24 | $988.0M | $628.0M | ||
| Q2 24 | $1.0B | $584.5M | ||
| Q1 24 | $1.0B | $491.3M |
净利润HOLXTTD
| Q4 25 | $179.1M | $186.9M | ||
| Q3 25 | $187.2M | $115.5M | ||
| Q2 25 | $194.9M | $90.1M | ||
| Q1 25 | $-17.4M | $50.7M | ||
| Q4 24 | $201.0M | $182.2M | ||
| Q3 24 | $178.6M | $94.2M | ||
| Q2 24 | $194.5M | $85.0M | ||
| Q1 24 | $169.9M | $31.7M |
毛利率HOLXTTD
| Q4 25 | 56.0% | 80.7% | ||
| Q3 25 | 55.6% | 78.1% | ||
| Q2 25 | 56.3% | 78.2% | ||
| Q1 25 | 37.5% | 76.8% | ||
| Q4 24 | 56.8% | 81.7% | ||
| Q3 24 | 56.4% | 80.5% | ||
| Q2 24 | 55.4% | 81.1% | ||
| Q1 24 | 53.3% | 78.9% |
营业利润率HOLXTTD
| Q4 25 | 22.6% | 30.3% | ||
| Q3 25 | 22.6% | 21.8% | ||
| Q2 25 | 24.9% | 16.8% | ||
| Q1 25 | -0.7% | 8.8% | ||
| Q4 24 | 22.5% | 26.4% | ||
| Q3 24 | 23.3% | 17.3% | ||
| Q2 24 | 24.1% | 16.2% | ||
| Q1 24 | 20.7% | 5.8% |
净利率HOLXTTD
| Q4 25 | 17.1% | 22.1% | ||
| Q3 25 | 17.8% | 15.6% | ||
| Q2 25 | 19.0% | 13.0% | ||
| Q1 25 | -1.7% | 8.2% | ||
| Q4 24 | 19.7% | 24.6% | ||
| Q3 24 | 18.1% | 15.0% | ||
| Q2 24 | 19.2% | 14.5% | ||
| Q1 24 | 16.7% | 6.4% |
每股收益（稀释后）HOLXTTD
| Q4 25 | $0.79 | $0.39 | ||
| Q3 25 | $0.84 | $0.23 | ||
| Q2 25 | $0.86 | $0.18 | ||
| Q1 25 | $-0.08 | $0.10 | ||
| Q4 24 | $0.87 | $0.36 | ||
| Q3 24 | $0.75 | $0.19 | ||
| Q2 24 | $0.82 | $0.17 | ||
| Q1 24 | $0.72 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $1.3B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $2.5B |
| 总资产 | $9.2B | $6.2B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXTTD
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.9B | $1.7B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $2.0B | $1.9B | ||
| Q3 24 | $2.3B | $1.7B | ||
| Q2 24 | $2.4B | $1.5B | ||
| Q1 24 | $2.2B | $1.4B |
总债务HOLXTTD
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
股东权益HOLXTTD
| Q4 25 | $5.2B | $2.5B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $4.8B | $2.7B | ||
| Q1 25 | $4.6B | $2.7B | ||
| Q4 24 | $4.8B | $2.9B | ||
| Q3 24 | $5.1B | $2.6B | ||
| Q2 24 | $5.0B | $2.4B | ||
| Q1 24 | $4.8B | $2.2B |
总资产HOLXTTD
| Q4 25 | $9.2B | $6.2B | ||
| Q3 25 | $9.0B | $5.9B | ||
| Q2 25 | $8.8B | $6.0B | ||
| Q1 25 | $8.5B | $5.7B | ||
| Q4 24 | $8.7B | $6.1B | ||
| Q3 24 | $9.2B | $5.5B | ||
| Q2 24 | $8.9B | $5.2B | ||
| Q1 24 | $8.7B | $4.7B |
负债/权益比HOLXTTD
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $311.6M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $285.3M |
| 自由现金流率自由现金流/营收 | 20.5% | 33.7% |
| 资本支出强度资本支出/营收 | 1.4% | 3.1% |
| 现金转化率经营现金流/净利润 | 1.28× | 1.67× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $795.7M |
8季度趋势，按日历期对齐
经营现金流HOLXTTD
| Q4 25 | $229.9M | $311.6M | ||
| Q3 25 | $355.1M | $224.7M | ||
| Q2 25 | $343.3M | $165.0M | ||
| Q1 25 | $169.4M | $291.4M | ||
| Q4 24 | $189.3M | $199.4M | ||
| Q3 24 | $367.0M | $273.3M | ||
| Q2 24 | $405.8M | $81.3M | ||
| Q1 24 | $292.4M | $185.5M |
自由现金流HOLXTTD
| Q4 25 | $215.2M | $285.3M | ||
| Q3 25 | $341.4M | $158.3M | ||
| Q2 25 | $330.5M | $119.8M | ||
| Q1 25 | $153.9M | $232.3M | ||
| Q4 24 | $172.5M | $179.2M | ||
| Q3 24 | $350.6M | $224.6M | ||
| Q2 24 | $385.3M | $59.1M | ||
| Q1 24 | $279.6M | $178.2M |
自由现金流率HOLXTTD
| Q4 25 | 20.5% | 33.7% | ||
| Q3 25 | 32.5% | 21.4% | ||
| Q2 25 | 32.3% | 17.3% | ||
| Q1 25 | 15.3% | 37.7% | ||
| Q4 24 | 16.9% | 24.2% | ||
| Q3 24 | 35.5% | 35.8% | ||
| Q2 24 | 38.1% | 10.1% | ||
| Q1 24 | 27.5% | 36.3% |
资本支出强度HOLXTTD
| Q4 25 | 1.4% | 3.1% | ||
| Q3 25 | 1.3% | 9.0% | ||
| Q2 25 | 1.3% | 6.5% | ||
| Q1 25 | 1.5% | 9.6% | ||
| Q4 24 | 1.6% | 2.7% | ||
| Q3 24 | 1.7% | 7.8% | ||
| Q2 24 | 2.0% | 3.8% | ||
| Q1 24 | 1.3% | 1.5% |
现金转化率HOLXTTD
| Q4 25 | 1.28× | 1.67× | ||
| Q3 25 | 1.90× | 1.94× | ||
| Q2 25 | 1.76× | 1.83× | ||
| Q1 25 | — | 5.75× | ||
| Q4 24 | 0.94× | 1.09× | ||
| Q3 24 | 2.05× | 2.90× | ||
| Q2 24 | 2.09× | 0.96× | ||
| Q1 24 | 1.72× | 5.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
TTD
| Other | $427.2M | 50% |
| Non Us | $419.6M | 50% |
